Clinical Trials Logo

Clinical Trial Summary

The impact of a sojourn at 2500 m of high altitude for 26-30 h on constant work-rate exercise test time in patients with precapillary pulmonary hypertension


Clinical Trial Description

Patients with pulmonary hypertension will perform a constant work-rate exercise test at low altitude (450m) and at high altitude 2500m in a randomized-cross-over sequence protocol. The constant work-rate exercise test time and other measures will be assessed ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05131737
Study type Interventional
Source University of Zurich
Contact
Status Completed
Phase N/A
Start date October 18, 2021
Completion date April 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT05264324 - Maximal Exercise Capacity at 2500 m of High Altitude N/A
Completed NCT05112172 - Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m N/A
Completed NCT05089487 - Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension N/A
Completed NCT05107700 - Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m N/A
Completed NCT03165656 - Right Ventricular Function at Rest in Highlanders/Lowlanders
Completed NCT03165019 - Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
Completed NCT03165032 - Right Ventricular Function During Exercise in Highlanders/Lowlanders
Completed NCT03172429 - Cerebral Tissue Oxygenation in Highlanders/Lowlanders
Completed NCT01566565 - The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension Phase 1
Completed NCT01621061 - Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders N/A
Completed NCT01530464 - The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers Phase 1